ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Trovagene Completes Dosing of Patients Treated with Onvansertib, Decitabine in AML Trial
September 28, 2018Trovagene announced completion of the second dosing cohort of Onvansertib, its first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care decitabine, in its Phase 1b/2 clinical trial in
Pharma Sources Insight January 2025
